Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009), a biopharmaceutical company based in China, has announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for its drug candidate AFN0328. The drug is intended for the treatment of malignant tumors associated with HPV16/18 infection, including cervical cancer, anal cancer, vulvar cancer, vaginal cancer, penile cancer, and head and neck cancer. Persistent infection with the human papillomavirus (HPV) can lead to precancerous lesions or cancerous changes in the cervix, anus, vulva, vagina, and other regions. AFN0328, an mRNA drug that targets HPV-associated tumors, is under co-development with Hefei Afana Biotechnology Co., Ltd. Notably, there is currently no similar product available on the global market.- Flcube.com
Recent news:
-
Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA -
Sihuan Pharmaceutical's Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China -
Innovent Biologics' IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment -
CDE Includes Double-Crane's Hydroxocobalamine and Sanofi Genzyme's Fitusiran in Rare Disease Care Plan -
Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency
